Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 25, showing 5 Applications out of 122 total, starting on record 66, ending on 70

# Protocol No Study Title Investigator(s) & Site(s)

66.

ECCT/20/04/01   Solidarity
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kilifi Kemri-Wellcome (Kilifi county)
2. Kenya National Hospital (Nairobi City county)
3. Coast PGH (Mombasa county)
4. The Nairobi Hospital (Nairobi City county)
5. Aga Khan University Hospital (Nairobi City county)
6. Moi Teahing and Referal Hospital (Uasin Gishu county)
7. Kenyatta University teaching research and referal hospital (Kiambu county)
 
View

67.

ECCT/20/03/01   GlycoShig3
    A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries.   
Principal Investigator(s)
1. Fredrick Kipyegon Sawe
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Kericho
 
View

68.

ECCT/19/12/01   BOHEMIA PK400
    Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens in preparation for BOHEMIA cluster randomized controlled trial.   
Principal Investigator(s)
1. Marta Ferreira Maia
Site(s) in Kenya
Kilifi
 
View

69.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View

70.

ECCT/19/11/01   A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults.
    Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.   
Principal Investigator(s)
1. Melissa Kapulu
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View